Nurix Therapeutics (NRIX) Announces Extension of Strategic Collaboration with Sanofi (SNY) to Develop Novel Targeted Protein Degraders of STAT6
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Nurix (NRIX) PT Raised to $23 at RBC Capital
April 11, 2024 6:28 AM EDTRBC Capital analyst Gregory Renza raised the price target on Nurix (NASDAQ: NRIX) to $23.00 (from $22.00) while maintaining a Outperform rating.
The analyst comments "The 1Q fiscal 24 EPS report recapped NRIX's recent partnership extensions that expand the company's TPD footprint in the I&I space... More
JPMorgan Takeaways on Nurix (NRIX) Q1 Earnings
April 10, 2024 12:32 PM EDTJPMorgan analyst Eric Joseph reiterated an Overweight rating and $30.00 price target on Nurix (NASDAQ: NRIX).
The analyst comments "Nurix reported a 1Q loss per share of $0.76, with takeaways from the print being incremental to those from the companys AACR presentation, updated collaboration with SNY, and our recent discussion with mgmt. On NX-5948 (BTK degrader for B-cell malignancies), the... More
Nurix Therapeutics (NRIX) Reports First Clinical Evidence of CNS Activity of NX-5948
April 9, 2024 1:19 PM EDTNurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the presentation of the first findings of clinical responses in the brain for NX-5948, an orally available, selective degrader of Brutons tyrosine kinase (BTK). The presentation included case studies for two patients, one with CLL with CNS involvement and the other with PCNSL, each demonstrating clinically meaningful responses. The presentation also provided evidence of measurable drug levels in the CNS of multiple patients in the ongoing Phase... More
